PT  - JOURNAL ARTICLE
AU  - Patterson, Marc
AU  - Ramaswami, Uma
AU  - Donald, Aimee
AU  - Foltan, Tomas
AU  - Gautschi, Matthias
AU  - Hahn, Andreas
AU  - Jones, Simon
AU  - Kolnikova, Miriam
AU  - Arash-Kaps, Laila
AU  - Park, Julien
AU  - Reichmannová, Stella
AU  - Walterfarng, Mark
AU  - Wibawa, Pierre
AU  - Rohrbach, Marianne
AU  - Martakis, Kyriakos
AU  - Bremova-Ertl, Tatiana
AU  - Gissen, P.
TI  - Disease-Modifying, Neuroprotective Effect of N-acetyl-L-leucine in Adult and Pediatric Patients with Niemann–Pick disease type C
AID  - 10.1101/2024.10.11.24315318
DP  - 2024 Jan 01
TA  - medRxiv
PG  - 2024.10.11.24315318
4099  - http://medrxiv.org/content/early/2024/10/12/2024.10.11.24315318.short
4100  - http://medrxiv.org/content/early/2024/10/12/2024.10.11.24315318.full
AB  - Background The phase 3 randomized, placebo-controlled, crossover trial, IB1001-301, comparing N-acetyl-L-leucine (NALL) with placebo for the treatment of Niemann-Pick disease Type C (NPC) after 12 weeks met both its primary and secondary endpoints. In an open-label Extension Phase (EP) follow-up data have been obtained to evaluate the long-term effects of NALL for NPC. Here, we report on the safety and efficacy after 12 and 18 months of extended follow-up.Methods In the ongoing EP, pediatric and adult NPC patients received treatment with orally administered NALL 2-3 times per day in three tiers of weight-based dosing. The primary endpoint was the modified 5-domain Niemann-Pick disease type C Clinical Severity Scale (5-Domain NPC-CSS) (range 0-25 points; lower score representing better neurological status). Comparisons were made to the expected annual trajectory of decline (i.e. disease progression) on the 5-domain NPC-CSS established in published natural history studies. Analyses were also performed on exploratory endpoints including the 15-domain and 4-domain NPC-CSS and Scale for Assessment and Rating of Ataxia (SARA) scale.Results A total of 54 patients aged 5 to 67 years have been enrolled in the EP. After 12 months, the mean (SD) change from baseline on the 5-domain NPC-CSS was -0.32 (2.43) with NALL versus 1.5 (3.16) in the historical cohort (95% Confidence Interval, -3.11 to -0.53; p=0.007), corresponding to a 121% reduction in annual disease progression. After 18 months, the mean (SD) change was -0.067 (2.94) with NALL versus 2.25 (4.74) in the historical cohort (95% Confidence Interval, -4.17 to -0.46; p=0.017). The results of the 15-domain and 4-domain NPC-CSS were consistent with the primary analysis. The improvements in neurological signs and symptoms demonstrated in the Parent Study’s primary SARA endpoint were sustained over the long-term follow-up. NALL was well-tolerated, and no treatment-related serious AEs occurred.Conclusion In patients with NPC, treatment with NALL after 12 and 18 months was associated with a significant reduction in disease progression, demonstrating a disease-modifying, neuroprotective effect.Trial Registration Information The trial is registered with ClinicalTrials.gov (NCT05163288; registered 06-Dec-2021), EudraCT (2021-005356-10). The first patient was enrolled into the EP on 08-Mar-2023.Competing Interest StatementTBE received honoraria for lecturing from Actelion and Sanofi Genzyme and fees for the blinded rater services from IntraBio. M. Patterson is a shareholder in IntraBio and his institution has received research grants from Azafaros, Glycomine, Idorsia, Maggies Pearl, Takeda, and Zevra, and consulting fees (directed to his institution) from Zevra. U. Ramaswami has received research and/or investigator-initiated research grants from Amicus and Takeda and honoraria for advisory boards and lectures from Amicus, Takeda, and Sanofi. All other authors. The authors have no competing interests to declare that are relevant to the content of this article.Clinical TrialNCT05163288Clinical Protocols https://www.nejm.org/doi/full/10.1056/NEJMoa2310151#ap1 Funding StatementThe study was funded by IntraBio LtdAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Ethics Committee of Ludwig Maximilian University of Munich (211269) gave ethical approval for this work. The National Institute of Child Diseases Bratislava Ethics Committee (EudraCT 202100535610) gave ethical approval for this work. The Ethics Committee of General University Hospital in Prague (5622 SMEK) gave ethical approval for this work. The East Midlands, Derby Research Ethics Committee (1004498) gave ethical approval for this work. The Amsterdam UMC Locatie AMC Central Ethics Committee (NL79787.018.21) gave ethical approval for this work. The Mayo Clinic Institutional Review Board (22001734) gave ethical approval for this work. The Emory University Institutional Review Board (STUDY00003227) gave ethical approval for this work. The Ethics Committee of the Canton of Bern, Switzerland (BASEC 202200638) gave ethical approval for this work. The Victoria Human Research Ethics Committee (HREC86167MH2022) gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.Yes